Physician profile
Mohammad Yunus
NPI 1730165259
$6,350.71
in general payments reported to CMS, 2019-2025
36 companies · $955 in 2025
The $955 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $1,124 · 2021: $1,208 · 2022: $1,072 · 2023: $752 · 2024: $621 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.68 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Grifols USA, LLC | $877.21 | 2019-2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $539.68 | 2019-2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $417.94 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $341.50 | 2021-2024 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $315.08 | 2019-2025 | |
| Pfizer INC. | $243.95 | 2019-2025 | |
| Allergan, INC. | $237.33 | 2019-2020 | |
| Glaxosmithkline, LLC. | $236.94 | 2019-2024 | Trelegy Ellipta |
| Amgen INC. | $209.93 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $182.82 | 2019-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $173.34 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $154.36 | 2019-2021 | |
| Verona Pharma, INC. | $153.95 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $150.18 | 2024-2025 | Glassia, Entyvio |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $112.59 | 2021-2024 | |
| Csl Behring | $98.98 | 2020-2024 | Idelvion, Afstyla, Hemgenix |
| Insmed, INC. | $97.83 | 2024-2025 | Arikayce |
| Biohaven Pharmaceutical Holding Company LTD. | $74.05 | 2022 | |
| Vivus LLC | $69.22 | 2022 | |
| Vanda Pharmaceuticals INC. | $68.34 | 2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $45.42 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $35.60 | 2020 | |
| Biogen, INC. | $34.91 | 2021 | |
| Eisai INC. | $34.18 | 2021-2022 | |
| Vifor Pharma, INC. | $30.02 | 2024 | Veltassa |
| Dexcom, INC. | $29.81 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $27.60 | 2023 | Vyepti |
| Grt US Holding, INC. | $26.16 | 2022 | |
| Genzyme Corporation | $24.17 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $23.64 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $21.93 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.91 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.13 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $14.72 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $13.61 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Yunus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.